ClinConnect ClinConnect Logo
Search / Trial NCT06653101

Effect of Akkermansia Muciniphila Akk11 on Metabolic and Gut Health in Overweight and Obese Subjects

Launched by WECARE PROBIOTICS CO., LTD. · Oct 18, 2024

Trial Information

Current as of April 29, 2025

Completed

Keywords

ClinConnect Summary

This clinical trial is exploring whether taking probiotics—good bacteria that help with digestion—can help people who are overweight lose weight. Participants will take either a probiotic supplement or a placebo (a sugar pill with no active ingredients) to see which is more effective for weight loss. The study is open to adults aged 18 to 65 who have a certain level of body fat or body mass index, which indicates they are overweight. However, people with certain health conditions, such as gout or severe digestive issues, or those who have recently taken antibiotics, cannot join the study.

If you choose to participate, you will need to complete some questionnaires and keep a diary about your experiences during the trial. You will also attend a number of clinical visits to check your health. It’s important to know that this study is currently recruiting participants, which means they are looking for people to join. Overall, this trial aims to find out if probiotics can be a helpful tool for weight loss in overweight adults.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. 18-45 years old;
  • 2. BMI ≥ 24 kg/m2 or men with a body fat percentage of ≥ 25% and women with a body fat percentage of ≥ 30%;
  • 3. Normal liver function indexes;
  • 4. Willing to complete study-related questionnaires and diaries and complete all clinical visits.
  • Exclusion Criteria:
  • 1. Those who have been diagnosed with high uric acid or gout are not recommended to participate in the test;
  • 2. Psychiatric or neurological diseases, celiac disease, lactose intolerance, allergies;
  • 3. Have the following diseases: irritable bowel syndrome, ulcerative colitis, fatty liver, liver cirrhosis, etc.;
  • 4. Recently treated with antibiotics (i.e., \< 3 months prior to the start of the study);
  • 5. Participants who smoked more than 10 cigarettes per day were excluded;
  • 6. It is not recommended to participate in other special circumstances, such as those who are allergic to probiotic products;
  • 7. Pregnant and lactating women are not suitable for experiments.

About Wecare Probiotics Co., Ltd.

wecare probiotics co., ltd. is a leading biotechnology firm dedicated to advancing gut health through innovative probiotic solutions. With a robust portfolio of research and development initiatives, the company focuses on formulating high-quality probiotic products that are backed by scientific evidence. Committed to enhancing the well-being of individuals, wecare probiotics collaborates with healthcare professionals and academic institutions to conduct clinical trials that evaluate the efficacy and safety of its formulations. The company's mission is to empower consumers with effective, research-driven probiotic options, fostering a healthier future for all.

Locations

Zhengzhou, None Selected, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported